Negative in Ames, in vitro chromosome aberration (human lymphocytes) and in vivo rat micronucleus assays
“Daridorexant was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay or in the in vitro mammalian chromosome aberration assay in human lymphocytes and was not clastogenic in the in vivo rat micronucleus assay.”
2-year rat and 26-week Tg.rasH2 mouse: no increase in tumors
“Daridorexant did not increase the incidence of tumors in rats treated for 2 years at oral doses of 15, 50, and 150 mg/kg/day. The high dose of 150 mg/kg/day is approximately 4 times the MRHD of 50 mg, based on AUC. Daridorexant did not increase the incidence of tumors in Tg.rasH2 mice treated for 26 weeks”
Rat and rabbit EFD: no effects on embryo-fetal survival and no malformations
“Embryo-fetal development toxicity studies were conducted in rats and rabbits. Treatment-related effects on embryo-foetal survival or foetal malformations were not reported in any species.”
Weak hERG inhibition (IC50 25 µM); no adverse CNS, cardiovascular or respiratory effects at relevant levels
“In an in vitro hERG assay (Study T-14.012, GLP), daridorexant induced weak inhibition of the potassium current with an IC20 of 7.4µM (~3400 ng/mL) and IC50 of 25µM (~11500 ng/mL), respectively.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative